GRI Bio Highlights GRI-0621's Potential To Reduce Inflammation And Hepatic Fibrosis In Idiopathic Pulmonary Fibrosis, With Positive Preclinical Data Presented At AFDD Summit And Phase 2 Topline Data Expected In Q2 2025
GRI Bio Highlights GRI-0621's Potential To Reduce Inflammation And Hepatic Fibrosis In Idiopathic Pulmonary Fibrosis, With Positive Preclinical Data Presented At AFDD Summit And Phase 2 Topline Data Expected In Q2 2025
GRI生物製藥公司展示了GRI-0621減少特發性肺纖維化炎症和肝纖維化的潛力,該產品在AFDD峯會上公佈了積極的臨床前數據,並預計在2025年第二季度公佈2期臨床數據。
GRI Bio Highlights GRI-0621's Potential To Reduce Inflammation And Hepatic Fibrosis In Idiopathic Pulmonary Fibrosis, With Positive Preclinical Data Presented At AFDD Summit And Phase 2 Topline Data Expected In Q2 2025
GRI Bio 強調了 GRI-0621 減少特發性肺纖維化炎症和肝纖維化的潛力,在 AFDD 峯會上公佈了積極的臨床前數據,第二階段的頭條數據預計將於 2025 年第二季度公佈